TF and cancer: Finally, high FVIIa–AT levels predicted an increased risk of mortality in the cancer population during a 34-month median follow-up, thereby suggesting that FVIIa–AT may allow the identification of patients with cancer characterized by an enhanced TF expression and a greater risk of mortality [41].